)
Amgen (AMGN) investor relations material
Amgen Citi’s 2026 Virtual Oncology Leadership Summit summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic oncology R&D priorities
Focus on delivering transformative therapies, not marginal benefits, in both solid tumors and select hematological malignancies.
Two main pillars: T-cell engagers and precision small molecule therapies, with selective exploration of ADCs.
Long-term investment in T-cell engagers, with unique approvals in both hematological and solid tumors.
Selective external investments to complement internal pipeline and priorities.
Emphasis on leveraging in-house technology and data platforms, including deCODE and BiTE.
Product portfolio and clinical development
IMDELLTRA fully approved for second-line or later small cell lung cancer, with updated NCCN guidelines and broad U.S. adoption.
Multiple phase III trials for IMDELLTRA in various small cell lung cancer settings, aiming to expand indications.
Ongoing efforts to improve patient and provider convenience, including subcutaneous formulations and less frequent dosing.
LUMAKRAS expanding from lung to colorectal cancer, with promising combination data and ongoing phase III trials in earlier lines.
BLINCYTO advancing to earlier therapy lines and subcutaneous formulations, with potential expansion into autoimmune diseases.
Pipeline innovation and differentiation
Xaluritamig targets prostate cancer with a novel mechanism, aiming for broad patient eligibility and chemo-free regimens.
Phase III trials for xaluritamig focus on survival endpoints and address both pre- and post-taxane settings.
Early-stage studies for xaluritamig in neoadjuvant, biochemical recurrence, and hormone-sensitive prostate cancer.
Ewing sarcoma targeted due to high unmet need and strong biological rationale.
AMG 193 developed for MTAP-null tumors, with focus on lung and GI cancers and combination strategies.
Next Amgen earnings date
Next Amgen earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
American Biotechnology
Amgen is a biotechnology company from California with operations worldwide. Over the years, it has evolved from a fledgling start-up into a pharmaceutical titan, making a name for itself through its research and innovative drug development. Unlike traditional pharmaceutical companies, Amgen uses living cells to produce its products, a challenging approach that can yield groundbreaking results.
Born from Innovation
Amgen, founded in 1980 by William K. Bowes, Jr., George Rathmann, and Joseph Rubinfeld, set out to unlock the potential of biology for patients. The company's original focus was on tools for molecular biology, but it quickly shifted to human therapeutics. One of the company’s flagship treatments is Epogen, which revolutionized the treatment of anemia in patients with chronic kidney disease. Over the years, Amgen has expanded its portfolio of medications to tackle a variety of serious illnesses through a focus on research and development.
Some publicly traded peers operating in the same field include names such as Pfizer, Eli Lilly, Johnson & Johnson, and other large pharmaceutical companies.
A Therapeutic Pioneer
Amgen's extensive product portfolio caters to several therapeutic areas, from cardiovascular disease to oncology, nephrology, and more. Through a combination of biological and small molecule drugs, Amgen targets conditions where there is a high unmet medical need. Today, the company continues to place a big emphasis on research in medicine, striving for innovative solutions that improve the lives of its patients. The fact that Amgen uses living cells in some of their treatments has been a key part of their growth, but also their marketing over the years.
Serving Patients Worldwide
Amgen has expanded its footprint globally, bringing its products and therapies to patients around the world. The company's broad international presence in over 100 countries is supported by strategic partnerships, robust distribution networks, and a commitment to patient care.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage